Novartis AG (NVS)

73.98
0.25 0.34
NYSE : Health Technology
Prev Close 74.23
Open 74.77
Day Low/High 73.87 / 74.80
52 Wk Low/High 73.21 / 94.19
Volume 1.09M
Avg Volume 1.62M
Exchange NYSE
Shares Outstanding 2.62B
Market Cap 187.75B
EPS 3.30
P/E Ratio 22.43
Div & Yield 2.49 (3.36%)

Latest News

FDA Moves to Make Life Easier for Generic Drug Companies

FDA Moves to Make Life Easier for Generic Drug Companies

Following up on a pledge to accelerate generic drugs into the marketplace to stoke price competition, the agency signals pending reform of the Risk Evaluation and Mitigation Strategy.

Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

President Trump's appetite for TV and ratings is legendary and now the administration wants to require drug company TV ads to include the list price of prescription drugs.

FDA Publicly Shames Drug Companies to Encourage Generic Competition

FDA Publicly Shames Drug Companies to Encourage Generic Competition

Following up on President Trump's drug pricing speech last week, the FDA posted a list of 39 name-brand drug firms that are allegedly making life tough on generic drug companies.

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Here's what you need to know now for Friday, May 18.

Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

Aimovig is the first treatment approved by the agency to prevent migraines by blocking the calcitonin gene-related peptide receptor.

Novartis Now Is Subject to Michael Cohen-Related Probes on 2 Continents

Novartis Now Is Subject to Michael Cohen-Related Probes on 2 Continents

Last week, the Swiss drug giant's $1.2 million in payments to President Trump's fixer Michael Cohen became public. Now the government of Switzerland as well as two U.S. senators are looking into them.

Trade Wars, AT&T's Cohen Drama and Nvidia's Big Beat - 5 Things You Must Know

Trade Wars, AT&T's Cohen Drama and Nvidia's Big Beat - 5 Things You Must Know

U.S. stock futures are slightly higher Friday as Wall Street prepares for the Trump administration's North Korea summit and China trade talks. AT&T and Novartis pick up the pieces. JPMorgan overhauls stock trading.

Novartis Ties to Trump Lawyer Michael Cohen Exposed

Novartis Ties to Trump Lawyer Michael Cohen Exposed

Pharma giant Novartis is now immersed in the muck that is the Trump-Russia probe thanks to $1.2 million in payments to a shell company created by President Trump's fixer Michael Cohen.

Iran Deal, Disney's Earnings and Changes at Facebook - 5 Things You Must Know

Iran Deal, Disney's Earnings and Changes at Facebook - 5 Things You Must Know

U.S. stock futures are higher Wednesday morning as Wall Street digests President Trump's decision to exit the Iran deal. Disney beat on the top and bottom line, while Facebook is making major changes to its executive leadership.

Teva Shows Progress on Restructuring But Investors Want More

Teva Shows Progress on Restructuring But Investors Want More

The Israel-based drugmaker reported first-quarter numbers that surpassed analysts' expectations but Wall Street wants to see more.

What to Expect From Allergan, Aetna, Merck and Pfizer's Earnings Next Week

What to Expect From Allergan, Aetna, Merck and Pfizer's Earnings Next Week

The drugmakers and health insurer are preparing to unveil first-quarter numbers.

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

The tough news keeps coming at the generic drug company, which announced last week it was considering putting itself up for sale. Now the Justice Department wants a chat.

Fate of Pfizer Unit in Spotlight After Merck Sells Consumer Business

Fate of Pfizer Unit in Spotlight After Merck Sells Consumer Business

Procter & Gamble, which is buying the Merck unit, was previously reported to be in talks to acquire Pfizer's consumer healthcare business.

Starbucks Leaves a Bitter Taste and Doesn't Suit My Investment Palate Either

Starbucks Leaves a Bitter Taste and Doesn't Suit My Investment Palate Either

For my portfolio, you can't beat this SBUX competitor -- and for a cup of coffee.

Ultragenyx Pharmaceutical Wins Approval for Drug Treating Rare Form of Rickets

Ultragenyx Pharmaceutical Wins Approval for Drug Treating Rare Form of Rickets

Ultragenyx scored its second FDA drug approval in six months. The orphan disease specialist also picked up its second Rare Pediatric Disease Priority Review Voucher; its first sold for $130 million.

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer and our other experts discuss the FAANG stocks, a market bottom, and potential biotech targets.

3 Potential Biotech Buyout Targets in the Second Quarter

3 Potential Biotech Buyout Targets in the Second Quarter

Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.

Getting Ready for Biotech Earnings

Getting Ready for Biotech Earnings

Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.

We Got Too Negative: Cramer's 'Mad Money' Recap (Monday 4/9/18)

We Got Too Negative: Cramer's 'Mad Money' Recap (Monday 4/9/18)

Jim Cramer says we're seeing powerful reminders that there's a better time to sell than in the teeth of a decline. Investors must use discipline to their advantage.

Markets Keep Eye on China Presidential Speech; Biotechs Bounce -- ICYMI

Markets Keep Eye on China Presidential Speech; Biotechs Bounce -- ICYMI

Here's what you need to know for Monday, April 9.

Stocks Rise on Softer U.S. Approach in China Trade War

Stocks Rise on Softer U.S. Approach in China Trade War

Stocks rise Monday following tweets from Donald Trump that appeared to indicate the U.S. was softening its approach in its trade battle with China.

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

Stock Market's Overhead Resistance Is Now More Powerful Than V-Shaped Bounces

Stock Market's Overhead Resistance Is Now More Powerful Than V-Shaped Bounces

Two failed bounces this year have made it tougher for stocks to build strong sustained momentum.

Stock Futures Are on a Mild Tear Monday After Brutal Friday Selloff

Stock Futures Are on a Mild Tear Monday After Brutal Friday Selloff

Markets around the globe last week were tumultuous after both China and the U.S. proposed tariffs on imported goods as investors weigh whether the countries will come to the table to negotiate an end to the spat.

5 Thing You Must Know Before Monday's Opening Bell

5 Thing You Must Know Before Monday's Opening Bell

U.S. stock futures rise Monday following indications that Donald Trump was softening his approach toward China; Deutsche Bank ousts CEO John Cryan; Novartis buys AveXis; Facebook to notify users whose data may have been shared with Cambridge Analytica.

TheStreet Quant Rating: B- (Buy)